Mark E. Whitlock
Granta Park
Cambridge, ENG, United Kingdom
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Intravenous Infusions of PF-07304814 (Lufotrelvir) in Participants Hospitalized With COVID-19.
Journal: Open forum infectious diseases
Published: December 23, 2022
A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes.
Journal: Diabetes, obesity & metabolism
Published: August 31, 2022
Mixed meal tolerance testing highlights in diabetes altered branched-chain ketoacid metabolism and pathways associated with all-cause mortality.
Journal: The American journal of clinical nutrition
Published: July 06, 2022
Safety, Tolerability, and Pharmacokinetics of Multiple Repeated Oral Doses of the α2/3/5-Subtype Selective GABAA -Positive Allosteric Modulator PF-06372865 in Healthy Volunteers.
Journal: Clinical pharmacology in drug development
Published: September 02, 2020
Is High Placebo Response Really a Problem in Depression Trials? A Critical Re-analysis of Depression Studies.
Journal: Innovations in clinical neuroscience
Published: December 14, 2019
An 8-Week, Randomized, Phase 2, Double-Blind, Sequential Parallel-Group Comparison Study of Two Dose Levels of the GABAA Positive Allosteric Modulator PF-06372865 Compared With Placebo as an Adjunctive Treatment in Outpatients With Inadequate Response to Standard of Care for Generalized Anxiety Disorder.
Journal: Journal of clinical psychopharmacology
Published: December 12, 2018
Response to "Treating patients rather than their functional neuroimages" (Br J Anaesth 2018; 121: 969-71).
Journal: British journal of anaesthesia
Published: November 12, 2018
Analgesic potential of PF-06372865, an α2/α3/α5 subtype-selective GABAA partial agonist, in humans.
Journal: British journal of anaesthesia
Published: July 25, 2018
Photosensitive epilepsy: Robust clinical efficacy of a selective GABA potentiator.
Journal: Neurology
Published: June 26, 2018
Audio Recording for Independent Confirmation of Clinical Assessments in Generalized Anxiety Disorder.
Journal: Innovations in clinical neuroscience
Published: May 04, 2018
Pharmacology in translation: the preclinical and early clinical profile of the novel α2/3 functionally selective GABAA receptor positive allosteric modulator PF-06372865.
Journal: British journal of pharmacology
Published: June 30, 2017
Last Updated: 09/26/2026